Morepen Laboratories Ltd
Morepen Laboratories Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
FY25 revenue target is around Rs. Morepen expects modest revenue growth of 10%-15% in the near term, with a long-term CAGR target of around 17%-18% depending on market conditions (Page 16, 27). - For FY25, a target of around Rs.
From Morepen Laboratories Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY25 revenue target is around Rs. 1,900 crore with 10%-11% growth, not official guidance but expected.
- Pharma business expected to grow modestly; API business growth expected between 10%-15% based on market conditions.
- Formulation and OTC business projected to grow around 25% in FY26 with overall EBITDA margins of 11%-12%.
- Medical devices grew 15% in Q3 compared to last year; expected CAGR of about 20% over the long term.
- Glucometer base expanding; 13.5 million meters installed driving strip sales.
- Capacity expansions (API capacity increasing from 510 KL to 600 KL) to support growth over next 6-9 months.
- Expected market corrections with some quarters slow; long-term view remains positive.
2 more points from Morepen Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Morepen Laboratories is expanding API capacities with a total planned capacity of 600 KL, of which 510 KL is already completed and ready for production. The remaining capacity will be completed within 6 to 9 months.
- The P8 plant has been inaugurated with installation of 6 big reactors and 2 small reactors, P9 block construction is ongoing, followed by expansion of P10.
- New 120,000 sq. ft. facility construction is nearly complete (around 70% finished last update) for production and expansion.
- Medical devices capacity is being expanded: BP monitor capacity increased in existing facilities, glucose monitor capacity also being expanded.
- The new building will house around 20 additional injection molding machines, speeding up manufacturing.
2 more points from Morepen Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Regarding the current and expected order book, Sushil Suri mentions that in the last quarter (Q4), the API segment usually receives good orders from international customers as they place new orders in January and February after year-end closing.
- However, he notes it is too early to comment specifically on the current quarter's order book or provide guidance.
- Prices are stabilizing, which is positive for new order formation, but demand needs time to pick up after a typically quiet March quarter due to trade business inventory reductions and tax/GST payments.
2 more points from Morepen Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Labs.'s management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q3 FY25 results?
FY25 revenue target is around Rs. Morepen expects modest revenue growth of 10%-15% in the near term, with a long-term CAGR target of around 17%-18% depending on market conditions (Page 16, 27). - For FY25, a target of around Rs.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 35.9 with a market cap of ₹4,216 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Morepen Laboratories is expanding API capacities with a total planned capacity of 600 KL, of which 510 KL is already completed and ready for production.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.